Vor Biopharma Inc. (VOR)

Market Cap	63.90M
Revenue (ttm)	n/a
Net Income (ttm)	-118.09M
Shares Out	68.40M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	671,545
Open	0.970
Previous Close	0.958
Day's Range	0.906 - 0.990
52-Week Range	0.700 - 3.140
Beta	-0.34
Analysts	Strong Buy
Price Target	10.92 (+1,068.92%)
Earnings Date	Nov 5, 2024

About VOR

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 168
• Stock Exchange: NASDAQ
• Ticker Symbol: VOR
• Website: https://www.vorbio.com

Analyst Forecast

According to 6 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price forecast is $10.92, which is an increase of 1,068.92% from the latest price.

Price Target

$10.92

(1,068.92% upside)

Analyst Consensus: Strong Buy